These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 22282479)

  • 21. Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy.
    Álvarez JC; Cuervo SI; Garzón JR; Gómez JC; Díaz JA; Silva E; Sánchez R; Cortés JA
    BMC Pharmacol Toxicol; 2013 Nov; 14():59. PubMed ID: 24286231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study.
    Aardema H; Nannan Panday P; Wessels M; van Hateren K; Dieperink W; Kosterink JGW; Alffenaar JW; Zijlstra JG
    Int J Antimicrob Agents; 2017 Jul; 50(1):68-73. PubMed ID: 28501674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B; Mahul M; Breilh D; Legeron R; Signe J; Jean-Pierre H; Uhlemann AC; Molinari N; Jaber S
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration.
    Arzuaga A; Maynar J; Gascón AR; Isla A; Corral E; Fonseca F; Sánchez-Izquierdo JA; Rello J; Canut A; Pedraz JL
    J Clin Pharmacol; 2005 Feb; 45(2):168-76. PubMed ID: 15647409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.
    Cohen-Wolkowiez M; Watt KM; Zhou C; Bloom BT; Poindexter B; Castro L; Gao J; Capparelli EV; Benjamin DK; Smith PB
    Antimicrob Agents Chemother; 2014 May; 58(5):2856-65. PubMed ID: 24614369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC; Fleming MR; Healy DP; Chung CE; Shea KM; Humphrey ML; Kays MB
    Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
    Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
    Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case-control study of drug monitoring of β-lactams in obese critically ill patients.
    Hites M; Taccone FS; Wolff F; Cotton F; Beumier M; De Backer D; Roisin S; Lorent S; Surin R; Seyler L; Vincent JL; Jacobs F
    Antimicrob Agents Chemother; 2013 Feb; 57(2):708-15. PubMed ID: 23147743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
    Landersdorfer CB; Bulitta JB; Kirkpatrick CM; Kinzig M; Holzgrabe U; Drusano GL; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5715-23. PubMed ID: 22908169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
    Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
    J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.